RonaldLShazerMD
Internal Medicine • San Diego, CAHospital Medicine/Hospitalist
Vice President, Clinical Development
Dr. Shazer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3545 Cray Ct
San Diego, CA 92121Phone+1 858-529-7039- Is this information wrong?
Education & Training
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2001 - 2004
New York Medical CollegeClass of 2001
UCLA Anderson School of ManagementMBA
Certifications & Licensure
CA State Medical License 2002 - 2024
Clinical Trials
- Single-dose Safety Study of APD916 in Healthy Volunteers Start of enrollment: 2010 Mar 01
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study Start of enrollment: 2021 Jun 30
- Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors Start of enrollment: 2008 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsMRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, ...> ;Cancer Discovery. 2023 Nov 1
- 6 citationsMRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
- 19 citationsAntitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.Marc Oliva, Douglas B. Chepeha, Daniel Vilarim Araujo, J. Javier Díaz-Mejía, Peter Olson, Amy Prawira, Anna Spreafico, Scott V. Bratman, Tina Shek, John R. de Almeida,...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
- Join now to see all
Press Mentions
First Patient Dosed in Pivotal Biomarker-Guided Phase 3 Study of First Line Therapy with DB102 (Enzastaurin) + R-CHOP in Patients with High-Risk Diffuse Large B-cell Lymphoma (DLBCL)April 3rd, 2018- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop HospitalOctober 4th, 2017
- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of MedicineOctober 2nd, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
